Healthcare -
Drug Manufacturers - General - NYSE - US
$ 55.19
-0.199 %
$ 112 B
Market Cap
-12.51
P/E
1. INTRINSIC VALUE
Balance Sheet
Bristol-Myers Squibb Company
| Current Assets | 29.8 B |
| Cash & Short-Term Investments | 10.9 B |
| Receivables | 10.7 B |
| Other Current Assets | 8.17 B |
| Non-Current Assets | 62.8 B |
| Long-Term Investments | 0 |
| PP&E | 7.14 B |
| Other Non-Current Assets | 55.7 B |
| Current Liabilities | 23.8 B |
| Accounts Payable | 3.6 B |
| Short-Term Debt | 2.23 B |
| Other Current Liabilities | 17.9 B |
| Non-Current Liabilities | 52.4 B |
| Long-Term Debt | 49 B |
| Other Non-Current Liabilities | 3.47 B |
EFFICIENCY
Earnings Waterfall
Bristol-Myers Squibb Company
| Revenue | 48.3 B |
| Cost Of Revenue | 11.9 B |
| Gross Profit | 36.4 B |
| Operating Expenses | 19.6 B |
| Operating Income | 0 |
| Other Expenses | 8.93 B |
| Net Income | -8.93 B |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Bristol-Myers Squibb Company
| Net Income | -8.93 B |
| Depreciation & Amortization | 9.6 B |
| Capital Expenditures | -1.25 B |
| Stock-Based Compensation | 507 M |
| Change in Working Capital | 810 M |
| Others | 16.1 B |
| Free Cash Flow | 13.9 B |
Wall Street Analysts Price Targets
Bristol-Myers Squibb Company
Wall Street analysts predict an average 1-year price target for BMY of $53.4 , with forecasts ranging from
a
low of
$41 to a high of $67 .
BMY Lowest Price Target
Wall Street Target
41 USD
-25.71%
BMY Average Price Target
Wall Street Target
53.4 USD
-3.19%
BMY Highest Price Target
Wall Street Target
67 USD
21.40%
4. DIVIDEND
ANALYSIS
1.06%
DIVIDEND YIELD
0.62 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Bristol-Myers Squibb Company
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
38.9 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
210 K USD 2
0-3 MONTHS
100 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
4 Blue Chip Pharmaceutical High-Yield Dividend Stocks Are Tariff Winners
With some pharmaceutical stocks paying 4% and higher dividends, they may be the perfect total return idea for the rest of 2025.
247wallst.com
- 2 weeks ago
Hedge Funds Are Dumping Tech Stocks: Grab These 4 Safety Net High-Yield Dividend Giants Now
Hedge funds are rapidly reducing their exposure to global information technology stocks, with the latest selloff marking the fastest decline in six months.
247wallst.com
- 2 weeks ago
Is Bristol Myers Squibb's High-Yielding Dividend Safe?
High-yielding dividend stocks can be great investments to hold on to in your portfolio, but only if they're safe. Betting on a high yield can be dangerous because if it ends up getting cut, you could lose all or most of the dividend income, and the stock may crash in the process as dividend investors could look elsewhere for a high payout.
fool.com
- 2 weeks ago
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer.
zacks.com
- 2 weeks ago
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
cnbc.com
- 2 weeks ago
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
zacks.com
- 2 weeks ago
Beat the S&P 500 With This Cash-Gushing Dividend Stock
Investors seeking relief from stock market volatility should take a closer look at Bristol Myers Squibb (BMY 1.77%). At the time of writing, shares of the healthcare giant have climbed 4% year to date -- a notable outlier amid the broader stock market sell-off, with the S&P 500 index currently down nearly 10% from its peak.
fool.com
- 2 weeks ago
Final Trade: DIS, BMY, AMZN, XMAG
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
youtube.com
- 3 weeks ago
Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Surgery and Adjuvant Opdivo.
businesswire.com
- 3 weeks ago
Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications.
businesswire.com
- 3 weeks ago
3 Deeply Discounted Dividend Stocks to Buy Today
Want to buy a good dividend stock and secure a great price in the process? I have a list of three stocks that can help you diversify your portfolio, allow you to earn above-average dividends, and score some potential bargains in the process.
fool.com
- 3 weeks ago
Bristol Myers Squibb (BMY) Rises As Market Takes a Dip: Key Facts
Bristol Myers Squibb (BMY) closed the most recent trading day at $59.21, moving +0.03% from the previous trading session.
zacks.com
- 3 weeks ago
8. Profile
Summary
Bristol-Myers Squibb Company BMY
COUNTRY
US
INDUSTRY
Drug Manufacturers - General
MARKET CAP
$ 112 B
Dividend Yield
1.06%
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Contact
430 East 29th Street, New York, NY, 10016
https://www.bms.com
IPO
Date
June 1, 1972
Employees
34100
Officers
Ms. Karin Shanahan
Executive Vice President of Global Product Development & Supply
Ms. Ahn Amanda Poole
Executive Vice President & Chief Human Resources Officer
Ms. Sandra Leung Esq.
Executive Vice President & General Counsel
Mr. Greg Meyers
Executive Vice President and Chief Digital & Technology Officer
Mr. Samit Hirawat M.D.
Executive Vice President, Chief Medical Officer & Head of Development
Dr. Joseph J. Eiden Jr.
Head of Medical Affairs
Mr. Adam Lenkowsky
Executive Vice President & Chief Commercialization Officer
Ms. Kimberly M. Jablonski
Chief Compliance & Ethics Officer
Mr. David V. Elkins
Executive Vice President & Chief Financial Officer
Dr. Christopher S. Boerner Ph.D.
Chief Executive Officer & Chairman